Table 1 Baseline characteristics of the included patients and their endoscopies.
| Total (n = 386) | Early group (n = 132) | Late group (n = 128) | Split-dose group (n = 126) | |
| *Metoclopramide, ondansetron, erythromycin, domperidone, opioids, levodopa, tricyclic antidepressants, beta-agonists, anticholinergics. GI, gastrointestinal; NA, not applicable; p25-p75, 25 th to 75 th percentile; SD, standard deviation. | ||||
| Baseline characteristics patients | ||||
| Age , mean (SD) | 66 (12) | 66 (12) | 67 (13) | 66 (12) |
| Male , n (%) | 269 (70) | 92 (70) | 91 (71) | 86 (68) |
| ASA classification , n (%) | ||||
| I | 34 (9) | 10 (8) | 12 (9) | 12 (10) |
| II | 320 (83) | 115 (87) | 104 (81) | 101 (80) |
| III | 32 (8) | 7 (5) | 12 (9) | 13 (10) |
| Indication endoscopy , n (%) | ||||
| Barrett’s esophagus | 127 (33) | 46 (35) | 40 (31) | 41 (33) |
| Follow-up after treatment Barrett’s esophagus | 137 (35) | 42 (32) | 49 (38) | 46 (37) |
| Dyspepsia/epigastric pain | 41 (11) | 13 (10) | 14 (11) | 14 (11) |
| Gastroesophageal reflux | 21 (5) | 6 (5) | 7 (5) | 8 (6) |
| Anemia | 12 (3) | 5 (4) | 5 (4) | 2 (2) |
| Screening malignancy | 12 (3) | 5 (4) | 3 (2) | 4 (3) |
| Dysphagia | 6 (2) | 1 (0.8) | 2 (2) | 3 (2) |
| Suspected upper GI bleeding | 1 (0.3) | 0 (0) | 0 (0) | 1 (1) |
| Suspected celiac disease | 1 (0.3) | 0 (0) | 0 (0) | 1 (1) |
| Other | 28 (7) | 14 (11) | 8 (6) | 6 (5) |
| Diabetes mellitus , n (%) | 53 (14) | 22 (17) | 19 (15) | 12 (10) |
| Medication affecting gastric emptying *, n (%) | 68 (18) | 17 (13) | 28 (22) | 23 (18) |
| Baseline characteristics endoscopy | ||||
| Performing endoscopist | ||||
| Endoscopist 1 | 211 (55) | 70 (53) | 70 (55) | 71 (56) |
| Endoscopist 2 | 84 (22) | 28 (21) | 28 (22) | 28 (22) |
| Endoscopist 3 | 55 (14) | 19 (14) | 18 (14) | 18 (14) |
| Endoscopist 4 | 43 (11) | 15 (11) | 14 (11) | 14 (11) |
| Sedation , n (%) | ||||
| Midazolam/fentanyl | 239 (62) | 80 (61) | 82 (64) | 77 (61) |
| Propofol | 79 (20) | 27 (20) | 27 (21) | 25 (20) |
| No sedation | 68 (18) | 25 (19) | 19 (15) | 24 (19) |
| Timing simethicone , minutes, median (p25-p75) | ||||
| First simethicone drink | 25 (19–33) | NA | 25 (19–33) | |
| Second simethicone drink | NA | 8 (6–10) | 8 (6–9) | |
| Duration endoscopy , minutes, median (p25-p75) | 8 (5–13) | 8 (5–12) | 9 (6–14) | 9 (5–14) |